Axel Nielsen
Nessuna posizione attualmente
Profilo
Axel Nielsen has been Chief Operating Officer of deCODE genetics, Inc. since June 2007.
Previously, he was Chief Operating Officer of deCODE's US operations from June 1998 to 2002.
Mr. Nielsen was Vice President-Investor Relations, Vice President-Finance, Treasurer and Chief Financial Officer of deCODE genetics.
Before joining deCODE, he was with Icelandair, Inc. and McKinsey & Co. Mr. Nielsen received a BS degree in Computer Science and Finance from the University of Iceland and an MBA degree from MIT Sloan School of Management.
Precedenti posizioni note di Axel Nielsen
| Società | Posizione | Fine |
|---|---|---|
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Direttore operativo | 01/01/2010 |
Formazione di Axel Nielsen
| University of Iceland | Undergraduate Degree |
| Massachusetts Institute of Technology | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland. | Health Technology |
- Borsa valori
- Insiders
- Axel Nielsen
